Achieve Life Sciences, Inc. (ACHV) Stock Price & Analysis
Achieve Life Sciences, Inc. (ACHV) closed at USD 6.85 on Wednesday, October 28, 2026, down 1.15% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 6.93; the Oct 28, 2026 session ranged USD 6.68–6.97 on volume of 966,162 shares. Market capitalization is $706.25M, with a 52-week range of USD 2.62–8.64 (NCM). Source: Nexqual, retrieved October 29, 2026 at 11:43 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ACHV.md
Key facts (ACHV)
- Insider open-market sales, last ~7 months: 1 Form 4 filings, $175K; 1 not under a Rule 10b5-1 plan ($175K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 1.75 on a 1–5 scale) (12 analysts), mean target USD 14.15 (range 9–21).
- Total return with dividends: 1Y +38.4% vs S&P 500 +13.6%; 5Y -17.4% vs S&P 500 +79.8%.
- Next earnings: 2026-11-05, EPS estimate USD -0.19, revenue estimate $0K.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (ACHV)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Net income | -$33.2M | -$42.4M | -$29.8M | -$39.8M | -$54.6M | -$114M |
| EPS (diluted) | -$4.08 | -$4.00 | -$1.50 | -$1.24 | -$1.25 | — |
| Free cash flow | — | — | -$24.5M | — | -$49.5M | — |
| Cash + short-term investments | $43.0M | $24.8M | $15.5M | $34.4M | $36.4M | — |
| Total debt | $14.9M | — | — | $9.8M | $11.2M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (ACHV)
Earnings yield -16.15% · Net cash $180M · EV $526M
Insider sales (SEC Form 4, open-market, last ~7 months) (ACHV)
0 of 1 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-08-19 | Stewart Richard Alistair | Director | 20,626 | $175K | 9% | No | Too little history (no open-market trades in 2023) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (ACHV)
Consensus Buy (mean 1.75 on a 1–5 scale), 12 analysts; mean target USD 14.15 (low 9, high 21).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-30 | Stifel | Initiated | Buy | $18 |
| 2026-08-13 | Morgan Stanley | Initiated | Overweight | $13 |
Total return (dividends reinvested) (ACHV)
| 1Y (from 2025-10-29) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +38.4% | -17.4% |
| S&P 500 (SPY) | +13.6% | +79.8% |
| Per year | +38.5% | -3.7% |
| Volatility (annualized) | 80.6% | 77.9% |
| Max drawdown | -54.5% (Jan 2026→Mar 2026) | -77.2% (May 2023→Apr 2025) |
ACHV earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| Aug 11, 2026 | Quarter ended Jun 30, 2026 | −$0.80 | −$0.16 | Miss −400.0% | +0.3% |
| May 12, 2026 | Quarter ended Mar 31, 2026 | −$0.19 | −$0.30 | Beat +36.7% | +6.6% |
| Mar 24, 2026 | Quarter ended Dec 31, 2025 | −$0.28 | −$0.28 | In line | -30.4% |
| Nov 6, 2025 | Quarter ended Sep 30, 2025 | −$0.28 | −$0.26 | Miss −7.7% | -6.9% |
| Aug 7, 2025 | — | — | — | — | -5.3% |
| May 13, 2025 | — | — | — | — | +0.0% |
| Mar 11, 2025 | — | — | — | — | -13.4% |
| Nov 7, 2024 | — | — | — | — | -9.6% |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
ACHV recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Oct 1, 2026 | 8-K | Director or executive officer change, or pay arrangement “On October 1, 2026, Achieve Life Sciences, Inc. (the " Company ") announced that the Board of Directors of the Company (the " Board ") appointed Benjamin Halladay as the Company's Chief Financial Officer and "principal financial officer," effective as of October 5, 2026 (the " Appointment Date "). Before joining the Company, Mr. Halladay, age 40, served in several different roles at Esperion Therapeutics, Inc., a pharmaceutical company, including as Chief Financial Officer from November 2022 until September 2026,…” |
| Aug 17, 2026 | Schedule 13G | Logos Global Management LP, Logos Global Management GP LLC: 10.0% of shares, passive 5%+ holder |
| Aug 14, 2026 | 8-K | Other material event “On August 14, 2026, Achieve Life Sciences, Inc. (the "Company") entered into an Open Market Sale Agreement SM (the "Sales Agreement") with Jefferies LLC ("Jefferies"), under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.001 per share ("Common Stock"), having an aggregate offering price of up to $150.0 million (the "ATM Shares"), through Jefferies, as sales agent, pursuant to an at-the-market offering program (the "ATM Program"). The ATM…” |
| Aug 13, 2026 | Schedule 13G | JANUS HENDERSON GROUP Ltd.: 5.4% of shares, passive 5%+ holder |
| Aug 11, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Aug 11, 2026 | 8-K | Quarterly results |
| Jul 28, 2026 | Schedule 13G/A | Franklin Resources, Inc., Charles B. Johnson: 8.3% of shares, passive 5%+ holder (amended) |
| Jul 27, 2026 | Schedule 13G | BlackRock, Inc.: 5.1% of shares, passive 5%+ holder |
| Jul 8, 2026 | Schedule 13G | Vivo Opportunity Fund Holdings, L.P., Vivo Opportunity Co-Invest, L.P.: 5.0% of shares, passive 5%+ holder |
| Jul 6, 2026 | 8-K | Bylaws or fiscal-year change; Shareholder vote results |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
ACHV suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Extab | “On May 14, 2015, we entered into a Share Purchase Agreement with Sopharma to acquire 75% of the outstanding shares of Extab Corporation for $2.0 million in cash and $2.0 million in a deferred payment, contingent on regulatory approval of cytisinicline by the FDA or the European Medicines Agency.” |
Quoted from the company's 10-K filed Mar 24, 2026.
ACHV company outlook (results filed Aug 11, 2026)
- “Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for cytisinicline, an outcome the Company disclosed it anticipated in April 2026.”
- “The Company intends to resubmit its NDA naming Adare as its finished drug product manufacturer for commercial supply in the fourth quarter of 2026 and anticipates potential FDA approval in the first half of 2027, with U.S. commercial launch to follow.”
- “Scientific Data Advancement • Presented 52-week safety data from the ORCA-OL study at the American Thoracic Society (ATS) 2026 Annual Meeting, completing the anticipated clinical evidence package supporting the cytisinicline NDA.”
- “Proceeds are expected to fund the ORCA-V2 Phase 3 trial, the commercialization of cytisinicline, and working capital and general corporate purposes.”
Quoted word-for-word from the SEC 8-K results press release.
ACHV analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.19 | $-0.16 | −$0.03 | $0 | 12 |
| Next quarter (ends Dec 2026) | $-0.20 | $-0.19 | −$0.01 | $0 | 12 |
| Current fiscal year (ends Dec 2026) | $-1.38 | $-0.68 | −$0.70 | $0 | 11 |
| Next fiscal year (ends Dec 2027) | $-0.65 | $-0.49 | −$0.16 | $38.0M | 12 |
ACHV options: expected move
Options price a move of about ±27.6% (±$1.85) by Nov 20, 2026, which includes earnings on Nov 5, 2026. Over the last 8 reports the stock moved ±9.1% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 22 | 137.8% | ±27.6% |
| Dec 18, 2026 | 50 | 89.8% | ±25.0% |
| Jan 15, 2027 | 78 | 193.7% | ±39.9% |
| Mar 19, 2027 | 141 | 76.9% | ±41.7% |
30-day implied volatility 84.7% vs 55.2% realized over the last 30 trading days. Put/call ratio (volume) 0. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 29, 2026 at 11:43 UTC)
| Price | USD 6.85 |
|---|---|
| Change | ▼ 1.15% (down) |
| Previous Close | USD 6.93 |
| Open | USD 6.85 |
| Day Range | USD 6.68 – 6.97 |
| 52-Week Range | USD 2.62 – 8.64 |
| Volume | 966,162 shares |
| Market Cap | $706.25M |
| Exchange | NCM |
Technical Analysis (ACHV)
Nexqual's technical model rates ACHV "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 29, 2026 at 11:43 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 49.68 (neutral) |
| vs SMA50 | Below (USD 7.5) |
| MACD | -0.22 (negative) |
Analyst Ratings (ACHV)
Wall Street analysts rate ACHV "Buy" based on 12 analysts, with a mean price target of USD 14.15 (range USD 9–21), per Nexqual as of October 29, 2026 at 11:43 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 12 |
| Mean Target | USD 14.15 |
| High Target | USD 21 |
| Low Target | USD 9 |
| Buy / Hold / Sell | 12 / 0 / 0 |
Earnings (ACHV)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -0.19 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.8 vs est -0.16 ▼ miss |
| 2026-03-31 | USD -0.19 vs est -0.3 ▲ beat |
| 2025-12-31 | USD -0.28 vs est -0.28 ▼ miss |
| 2025-09-30 | USD -0.28 vs est -0.26 ▼ miss |
Source: Nexqual, October 29, 2026 at 11:43 UTC.
Financials & Fundamentals (ACHV)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -844.99% |
| Current Ratio | 0.95 |
| Total Cash | $187.30M |
| Total Debt | $14.95M |
Source: Nexqual, October 29, 2026 at 11:43 UTC.
Financial Health Score (ACHV)
Nexqual rates Achieve Life Sciences, Inc.'s overall financial health "Weak" across five dimensions, as of October 29, 2026 at 11:43 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $187M cash and investments vs $7M debt (Jun 2026, SEC), net cash |
| Cash Flow | Weak — Operating cash flow -$49M (FY ended Dec 2025, 10-K) |
| Efficiency | Critical — ROE not meaningful (negative equity); ROA -59.9% (last 4 quarters, SEC) |
Ownership (ACHV)
| Insider Ownership | +0.91% |
|---|---|
| Institutional Ownership | +82.23% |
| Shares Outstanding | 103.10M |
| Float | 74.69M |
| Short % of Float | +17.37% |
Source: Nexqual, October 29, 2026 at 11:43 UTC.
Leadership (ACHV)
Achieve Life Sciences, Inc. is led by Andrew D. Goldberg, CEO, President & Director, per Nexqual as of October 29, 2026 at 11:43 UTC.
| CEO, President & Director | Andrew D. Goldberg |
|---|---|
| Chief Financial Officer | Benjamin Halladay |
| Senior Vice President of Marketing & Communications | Kaitlyn Tuson |
| Senior Vice President of Commercial | Mark Zappia |
| Senior Vice President of Chemistry, Manufacturing & Controls and Supply Chain | Ronald Dadino |
Major Backers & Investors (ACHV)
Notable institutional backers of Achieve Life Sciences, Inc. include Frazier Life Sciences Management, L.P. , TPG GP A, LLC, venBio Partners LLC, according to Nexqual as of October 29, 2026 at 11:43 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Frazier Life Sciences Management, L.P. | 7.4% |
| TPG GP A, LLC | 6.68% |
| venBio Partners LLC | 5.75% |
| Logos Global Management LP | 5.27% |
| Franklin Resources, Inc. | 4.81% |
| Paradigm Biocapital Advisors LP | 4.81% |
| Propel Bio Management, LLC | 3.92% |
| Marshall Wace LLP | 3.66% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 5.12% |
| Vanguard Group | 4.02% |
Source: Nexqual, October 29, 2026 at 11:43 UTC.
From Achieve Life Sciences, Inc.'s Latest SEC 10-K Filing (filed 2026-03-24)
Key Strengths & Strategy (as disclosed to the SEC)
- In September 2025, we announced that the FDA accepted for review our New Drug Application, or NDA, for cytisinicline as a treatment for smoking cessation as the first indication in the United States and assigned a Prescription Drug User Fee Act, or PDUFA, targeted action date of June 20, 2026.
- In June 2017, we filed an Investigational New Drug Application, or IND, with the FDA, for evaluation of cytisinicline as a treatment for smoking cessation.
- In June 2022, following NIDA/NIH review of completed regulatory and clinical operational milestones plus acceptance of the IND by the FDA, we announced that we were awarded the next grant funding from NIDA in the amount of approximately $2.5 million.
- During 2022 and 2023, we had several Type C and Type D meetings with the FDA regarding the adequacy of our completed nonclinical studies, overall clinical pharmacology information, manufacturing product information, and our Integrated Safety Summary, or ISS, analysis plans for a future NDA submission.
Partnerships
- We have an exclusive license and a supply agreement with Sopharma for the development and commercialization of cytisinicline outside of Sopharma's territories, which are predominately located in Central and Eastern Europe.
- In the first quarter of 2024, we reached agreement with the FDA that a single, open-label study evaluating the long-term safety effects of cytisinicline would be sufficient to complete the requirement and enable an NDA submission.
Legal & Regulatory Risks (Item 1A, quoted)
- We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.
- Our employees, independent contractors, consultants, commercial partners, principal investigators, or CROs may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business.
- We rely on third parties to conduct our clinical trials and perform other services. If these third parties do not successfully perform and comply with regulatory requirements, we may not be able to successfully complete clinical development, obtain regulatory approval or commercialize cytisinicline and our business could be substantially harmed.
- We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability and other serious consequences for violations that can harm our business.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ORKA | Oruka Therapeutics, Inc. | USD 95.97 | ▲ 0.17% |
| LGND | Ligand Pharmaceuticals Incorpor | USD 318.78 | ▲ 2.26% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.81 | ▲ 1.58% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.9 | ▲ 2.14% |
| AXSM | Axsome Therapeutics, Inc. | USD 143.51 | ▲ 0.92% |
| ABVX | Abivax SA | USD 89.84 | ▲ 3.26% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 11:43 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt